Study of a new treatment for Alzheimer's disease in people taking lecanemab
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests a new treatment, called X/T, for people with Alzheimer's disease who are already taking lecanemab (Leqembi). The goal is to see if adding X/T is safe and tolerable, and if it might help manage symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 85 years old.
- You have a confirmed diagnosis of Alzheimer's disease.
- You have been taking lecanemab (Leqembi) for at least 14 infusions (about 7 months).
- You have a caregiver or study partner who can help you during the study.
- You are generally healthy, with no major heart, liver, or kidney problems.
- You are willing to stop certain medications that are not allowed during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the real-world experience of people with early Alzheimer's disease who are already taking lecanemab. It aims to better understand how the medication works and its safety in everyday medical practice.
This study looks at people who are taking or have taken lecanemab (a medication for Alzheimer's disease). It aims to gather more information about the treatment's effects in real-world settings.
This study tracks the safety of Leqembi (lecanemab), a treatment for Alzheimer's disease, in people who are already prescribed it in the UK. It helps doctors learn more about how the medicine affects patients in everyday life.
This study looks at the long-term effects of the Alzheimer's drug LEQEMBI (lecanemab) in people with mild memory problems or early Alzheimer's. It gathers information from patients who have already been taking the drug for 18 months to see how they are doing.
This study collects information from people in Canada who have Alzheimer's disease and are prescribed the drug lecanemab (LEQEMBI). It helps doctors learn more about the drug's safety and effects in real-world use.
This study observes people with Alzheimer's disease who are taking leqembi in Taiwan to learn more about how it works in everyday use. It may help understand the treatment's benefits and risks outside of clinical trials.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.